Mechanism of Action
Lipid II Sequestration
Ramoplanin inhibits bacterial cell wall synthesis by binding to Lipid II, the membrane-anchored peptidoglycan precursor. It sequesters Lipid II before transglycosylation can occur, blocking cell wall elongation and cross-linking. This mechanism is similar to vancomycin but occurs at a different Lipid II binding site, meaning ramoplanin retains activity against vancomycin-resistant organisms.
Membrane Disruption
In addition to Lipid II binding, ramoplanin disrupts bacterial membrane integrity, particularly at concentrations above the MIC. The lipid tail inserts into the bacterial membrane, causing depolarization and contributing to bactericidal activity. This dual mechanism reduces the likelihood of single-step resistance.
Research Summary
C. difficile Infection
Phase 3 (Discontinued)Phase 2 trials showed ramoplanin 200 mg BID was non-inferior to vancomycin for CDI treatment with a similar safety profile. Phase 3 trials were initiated but commercial development stalled primarily due to manufacturing scale-up difficulties with this structurally complex natural product.
VRE Decolonization
Phase 3 (Discontinued)Ramoplanin showed efficacy for decolonizing vancomycin-resistant Enterococcus from the gastrointestinal tract in Phase 2 studies. The non-absorbed oral formulation is ideal for gut decolonization, concentrating activity in the intestinal lumen while avoiding systemic toxicity.
Calculate your Ramoplanin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| CDI treatment (clinical trials) | 200 mg | Twice daily | Oral |
| VRE decolonization | 200 mg | Twice daily | Oral |
Not commercially available. Obtained through research programs or compounding for investigational use.
Interactions
Safety Profile
As a non-absorbed oral agent, ramoplanin has minimal systemic exposure and a favorable safety profile. Gastrointestinal adverse effects (nausea, abdominal pain) are the primary concerns. Systemic toxicity observed with parenteral administration is avoided with oral dosing. No significant drug interactions due to negligible systemic absorption.
References
- [1]Assign EI et al. (2007). Ramoplanin: a lipoglycodepsipeptide with in vitro activity against multiresistant bacteria. International Journal of Antimicrobial Agents, 29(1), 1-10.
- [2]McCafferty DG et al. (2002). Chemistry and biology of the ramoplanin family of peptide antibiotics. Chemistry & Biology, 9(5), 526-535.